Heather Preston
Managing Partner @ Pivotal bioVenture Partners
San Francisco, United States
Heather Preston is a Series B investor at Pivotal bioVenture Partners in San Francisco focused on Biotechnology and Pharmaceutical. Heather Preston has served on Otonomy’s board of directors since August 2010. Heather Preston is currently employed as a partner and managing director of TPG Biotech, a biotechnology venture capital firm. Heather Preston joined TPG in 2005. She currently serves on the board of directors of Alder Biopharmaceuticals, Inc., a public company and onthe boards of a number of private companies. Prior to joining TPG Biotech, Heather Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm. From 1997 to 2002, Heather Preston served as a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. in New York. Heather Preston holds a medical degree from the University of Oxford and a bachelor’s degree in biochemistry from the University of London. After leaving Oxford, Heather Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Heather Preston completed her training in internal medicine at the Massachusetts General Hospital and then subspecialized in gastroenterology and hepatology at the University of California, San Francisco. During Heather Preston’s academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-Doctoral Fellowship Award.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Heather Preston invests in
Stages Heather Preston invests in
Countries Heather Preston invests in
Investment Focus
Industry
- Biotechnology 8 (73%)
- Pharmaceutical 6 (55%)
- Health Care 5 (45%)
- Medical 4 (36%)
- Biopharma 2 (18%)
Stage
- Series B 7 (64%)
- Series C 3 (27%)
- Series D 1 (9%)
Country
- United States 6 (55%)
- Canada 1 (9%)
- Israel 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Avalyn Pharma
|
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $175M / Series C / Sep 27, 2023 | |
Arkuda Therapeutics
|
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-definedsubtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene. | $64M / Series B / Feb 10, 2022 | |
Azura Ophthalmics
|
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. | $20M / Series C / Oct 22, 2020 | |
|
Avalyn Pharma
|
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $35.5M / Series B / Apr 27, 2020 | |
Akouos
|
Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process,enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner. | $105M / Series B / Mar 03, 2020 | |
Fusion Pharmaceuticals
|
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.Fusion’s deepradiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link the most effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell.Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity. | $105M / Series B / Apr 02, 2019 | |
Karuna Therapeutics
|
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. | $68M / Series B / Mar 18, 2019 | |
|
Azura Ophthalmics
|
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. | $16M / Series B / Oct 10, 2017 | |
Entasis Therapeutics
|
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, includingETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae). | $31.9M / Series B / Sep 05, 2017 | |
Alder Biopharmaceuticals
|
Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Aldertoday will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs. | $38M / Series D / Apr 19, 2012 | |
| See all 11 investments → | |||
Co-Investors
About Pivotal bioVenture Partners
Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through midand late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.
Pivotal bioVenture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ash Khanna
Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune
|
|||
|
Heather Preston
Managing Partner
|
|||
Jeni Lee
Partner
|
|||
Robert Hopfner
Managing Partner
|
|||
|
Vincent Cheung
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Heather Preston invest in?
Heather Preston invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Heather Preston last invest?
The most recent investment recorded for Heather Preston closed in Sep 2023. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
